Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 3796 results
BioLineRx reports results from Phase 1/2 study for celiac treatment
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today unblinded results from its Phase 1/2 study for BL-7010, a novel polymer for the treatment of celiac disease.
Drug Research > Drug Discovery & Development > News
ChromaDex begins first human clinical study to confirm ChromaDex's NIAGEN Nicotinamide Riboside will increase NAD+
ChromaDex, an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the first human clinical study for its patented ingredient NIAGEN, the first and only commercially available form of nicotinamide riboside (NR).
Drug Research > Drug Discovery & Development > News
Roche's Phase III trial of melanoma combination therapy meets primary endpoint
By PBR Staff Writer
Roche has released positive results from the Phase III coBRIM trial of an investigational MEK inhibitor cobimetinib, used in combination with its BRAF inhibitor Zelboraf, to treat patients with previously untreated BRAF V600 mutation-positive advanced melanoma.
Drug Research > Drug Discovery & Development > News
Helix BioPharma announces completion of private placement
BioPharma, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, has announced it has completed a private placement with net proceeds in excess of CAD5.4 million, after fees and expenses associated with the placement.
Drug Research > Drug Discovery & Development > News
Ipsen, Galderma become exclusive partners for development and marketing of neurotoxins
Ipsen, a global specialty-driven pharmaceutical company, and Galderma, a global healthcare company focused on dermatology and skin health, has announced that they have significantly expanded the scope of their neurotoxin partnership.
Drug Research > Drug Discovery & Development > News
HD Biosciences, Marshall University enter drug discovery co-development deal
By PBR Staff Writer
HD Biosciences, a China-based biology-focused preclinical drug discovery contract research organization (CRO), the Marshall Institute for Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of Medicine have announced a new partnership to co-develop potential anti-cancer drugs for unmet healthcare needs in both international and Chinese markets.
Drug Research > Drug Discovery & Development > News
Threshold starts dosing in Phase I/II trial of myeloma combination drug TH-302/Bortezomib
By PBR Staff Writer
Threshold Pharmaceuticals has initiated dosing patients in the final stage of an ongoing Phase I/II trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib (Velcade) and low-dose dexamethasone (TBorD) for the treatment of relapsed/refractory multiple myeloma.
Drug Research > Drug Discovery & Development > News
Compugen discloses achievement of milestone in cancer immunotherapy collaboration with Bayer
Compugen has disclosed that it has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer).
Drug Research > Drug Discovery & Development > News
BioMarin gets Health Canada approval of VIMIZIM to treat morquio a syndrome
BioMarin Pharmaceutical has announced that Health Canada has approved VIMIZIM(elosulfase alfa) for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A syndrome.
Drug Research > Drug Discovery & Development > News
Yabao Pharma, Eli Lilly to jointly develop diabetes treatment
By PBR Staff Writer
China-based Yabao Pharmaceutical has entered into a strategic partnership with Eli Lilly and Company to jointly develop Lilly's glucokinase activator (GKA), LY2608204, which has completed Phase I studies in the US in addition to extensive pre-clinical development.
Drug Research > Drug Discovery & Development > News
Bayer's Nexavar gets Health Canada approval for differentiated thyroid cancer
Bayer is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Drug Research > Drug Discovery & Development > News
Celladon announces new clinical development initiatives for MYDICAR
Celladon Corporation has launched two new clinical development initiatives for MYDICAR(R), its lead product candidate, in patients with end-stage renal disease (ESRD) undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis, and in advanced heart failure patients with systolic dysfunction that were previously excluded from MYDICAR trials due to pre-existing levels of neutralizing antibodies.
Drug Research > Drug Discovery & Development > News
Debiopharm, Nobelex to develop new antibiotics for N. Gonorrhoeae and Enteric Species
By PBR Staff Writer
Swiss biopharmaceutical firm Debiopharm and Canada-based CAnaNobelex Biotech have entered into collaboration for two discovery programs for the development of new antibiotics targeting Neisseria gonorrhoeae and enteric species using a new mechanism of action.
Drug Research > Drug Discovery & Development > News
Morphotek, Sorrento to develop morphotek antibody drug conjugates
By PBR Staff Writer
Concortis Biosystems, a subsidiary of Sorrento Therapeutics, has announced a collaboration to develop new antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology.
Drug Research > Drug Discovery & Development > News
Orexo reports top-line data from Phase III trial of Zubsolv to treat opioid dependence
Orexo has announced top-line data from a Phase 3 clinical trial demonstrating that Zubsolv (buprenorphine/naloxone CIII sublingual tablet) is as effective as Suboxone film in the treatment of opioid dependence.
Drug Research > Drug Discovery & Development > News
91-105 of 3796 results